Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalunfiban in pre-hospital STEMI
NCT04825743Phase 3Active, not recruiting
- Sponsor
- CeleCor Therapeutics
- Start
- Apr 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of zalunfiban in ST elevation myocardial infarction (STEMI), sponsored by CeleCor Therapeutics. Started Apr 2021; status: active, not recruiting.
02
Drugs
zalunfiban
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04825743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825743.